<DOC>
	<DOCNO>NCT00297050</DOCNO>
	<brief_summary>This study evaluate safety tolerability peramivir , new drug treat influenza . The study administer gradually increase dos drug successive small group subject determine optimal dose safe well tolerate . It study first single dose multiple dos . The study also determine long peramivir stay body high drug level blood . Men woman 18 - 40 year age weigh least 110 lb . body mass index ( BMI ) 19 32 may eligible study . Candidates screen medical history , physical examination , electrocardiogram ( EKG ) , blood urine test . Part I - Single Dose Escalation Participants admit NIH hospital 32 40 hour single 15-minute intravenous infusion peramivir placebo ( saline ) , follow monitoring evaluation . The drug dose increase successive group eight subject ; group , six subject give peramivir two receive placebo . The first group receive 0.5 mg/kg peramivir ; subsequent group receive increasingly high dos ( 1 , 2 , 3.5 , 5 mg/kg ) long last dose well tolerated precede group . Blood sample draw subject monitor vital sign ( temperature , blood pressure heart rate ) symptoms headache , nausea , shortness breath pain 0.5 , 1 , 2 , 3 , 6 , 9 , 12 , 18 24 hour drug infusion . At 24-hour evaluation EKG . If need , echocardiogram ( ultrasound examination heart ) may also do . Subjects return clinic 2 , 3 , 7 , 14 , 28 day infusion check vital sign , review symptom , blood draw , urine sample collection . In addition , subject ask collect urine first 48 hour study drug infusion . Part II - Multi-dose Escalation Groups 16 subject receive intravenous infusion peramivir ( 12 subject ) placebo ( 4 subject ) day 5 consecutive day . The first four infusion give NIH outpatient clinic . The dose peramivir increase successive group 16 subject long precede dose well tolerate . Before infusion day 1 , subject physical examination , blood test EKG obtain baseline value . After infusion , remain hospital 6 hour . Vital sign symptom c ...</brief_summary>
	<brief_title>Safety Dose Study Peramivir Influenza Treatment</brief_title>
	<detailed_description>Human influenza serious disease cause 30,000 death United States year , avian influenza present threat future pandemic . Despite burden current potential disease , parenteral treatment influenza , currently , common treatment ( oseltamivir ) expensive complex manufacture . The primary purpose protocol evaluate safety tolerability intravenous peramivir , neuraminidase inhibitor . Beginning low single-dose , safety tolerability establish evaluate symptom , clinical laboratory test , ECG , pharmacokinetics . Utilizing series stopping rule medical monitor , dose escalate safety tolerability establish . Once maximum tolerate dose ( MTD ) establish first part trial ( either limited adverse effect maximum anticipated dose ) , safety tolerability multi-dose administration begin ( replicate anticipate clinical use ) . These cohort evaluate use similar criterion . The dose use multi-dose cohort also escalate safety tolerability establish .</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Peramivir</mesh_term>
	<criteria>INCLUSION CRITERIA : 1 . Age great equal 18 year less equal 50 year . 2 . Weight great equal 50 kg ( 110 lb ) . 3 . Body mass index ( BMI ) 1932 kg/m ( 2 ) . 4 . Subjects must agree : Not take prescription OTC medication exception Tylenol , contraceptive medication period 7 day prior study drug administration . Not consume alcohol period 2 day prior study drug administration . Not receive live attenuate influenza vaccine ( Flumist ) 7 day prior study drug administration , day 14 ( least 8 day last dose study drug ) . Not participate research protocol screening , last day followup . 5 . Females childbearing potential must ( one follow ) : Be surgically sterile . Be abstinent ( willing ) 4 week prior date screen evaluation 4 week study drug administration . Use oral contraceptive , form hormonal birth control include hormonal vaginal ring transdermal patch , use three month prior 4 week study drug administration . Use intrauterine device ( IUD ) birth control 4 week prior date screen evaluation 4 week study drug administration . Use ( ensure male partner ( ) use ) barrier contraception ( condom ) spermacide birth control 4 week prior date screen evaluation 4 week study drug administration . EXCLUSION CRITERIA : 1 . Any chronic medical problem require daily oral medication ( except Tylenol oral contraceptive ) , medical history opinion investigator significantly increase risk associate Phase I drug . 2 . History cardiovascular disease unexplained syncope 3 . Family history sudden death first degree relative . 4 . Women breastfeed . 5 . Positive urine serum pregnancy test . 6 . Abnormal ECG ( define baseline Grade 1 great toxicity toxicity table ECG . The toxicity table specifically evaluate PR interval , QTc interval rhythm . Asymptomatic sinus bradycardia , especially subject exercise , acceptable ) . 7 . Abnormal chemistry panel ( defined baseline Grade 1 great toxicity Chem 20 panel evaluate sodium , potassium , total CO2 ( bicarbonate ) , creatinine , glucose , urea nitrogen , total calcium , total magnesium , phosphorus , alkaline phosphatase , ALT , AST , total bilirubin , direct bilirubin , LDH , total protein , total CK , uric acid ) . 8 . Abnormal complete blood count ( CBC ) ( define baseline Grade 1 great toxicity CBC evaluate WBC , hemoglobin , hematocrit , platelet ) . 9 . Abnormal urinalysis ( defined baseline Grade 1 great toxicity urinalysis evaluate protein , RBCs ) . 10 . Positive serology Hepatitis B surface antigen . 11 . Positive serology Hepatitis C. 12 . Positive serology HIV1 . 13 . Positive urine drug screen . 14 . Participation study investigational drug within last 30 day .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>August 5, 2009</verification_date>
	<keyword>Influenza Virus</keyword>
	<keyword>Avian Influenza</keyword>
	<keyword>Normal Volunteers</keyword>
	<keyword>Neuraminidase Inhibitor</keyword>
	<keyword>Viral Disease</keyword>
	<keyword>Healthy Volunteer</keyword>
	<keyword>HV</keyword>
</DOC>